OR WAIT null SECS
© 2023 MJH Life Sciences and Applied Clinical Trials Online. All rights reserved.
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
May 22, 2023
In this Q&A, John Kastelein, MD, founder and chief scientific officer, NewAmsterdam Pharma, discusses the challenges and opportunities within the cardiovascular field, exploring the current landscape for lipid-lowering therapies and the unique potential advantages of CETP inhibitors.
May 16, 2023
Examining the two areas of weakness cited in FDA draft guidance.
Stakeholders must alter their mindsets when it comes to early-phase design and interpreting regulatory guidance for CGT trials.
May 10, 2023
Increased data output from the use of devices can accelerate trials for this therapeutic area in need of new therapies.
April 26, 2023
Thursday, May 25th, 2023 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
April 24, 2023
January 2023 guidance from FDA on dosages in oncology provides further context on expectations with Project Optimus.
March 27, 2023
Tiffany Chow, MD, a specialist in behavioral neurology and senior medical director at Alector, discusses the unique challenges of designing clinical trials for frontotemporal dementia.
March 07, 2023
Leal Health Poster Highlights Negative Impact of Patient ECOG Scores on Clinical Trial Enrollment Eligibility at 2023 ASCO GU Cancers Symposium.
February 16, 2023
Webinar Date/Time: Tue, Mar 28, 2023 11:00 AM EDT
February 14, 2023
Sanjay Shukla, MD, MS, CEO of aTyr Pharma, discusses the company's clinical operations and ongoing Phase III study for pulmonary sarcoidosis.